Drug General Information (ID: DDIU16VJQI)
Drug Name			Budesonide		Drug Info		Dinutuximab		Drug Info
Drug Type		Small molecule				Monoclonal antibody
Therapeutic Class		Antiinflammatory Agents				Antineoplastics

Mechanism of Budesonide-Dinutuximab Interaction (Severity Level: Major)
Additive immunosuppressive effects Click to Show/Hide Mechanism Graph
Drug Name		Budesonide				Dinutuximab
Mechanism		Immunosuppressive effects				Immunosuppressive effects
Key Mechanism Factor 1
		Factor Name		Immunosuppressive effects
		Factor Description		Immunosuppression is when your immune system is not functioning as it should. The immune system is made up of cells, tissues and organs that help the body fight off infections. If the immune system is suppressed, an infection that your body was able to control may become serious or even fatal.
Mechanism Description		Additive immunosuppressive effects by the combination of Budesonide and Dinutuximab

Recommended Action
Management		The manufacturer of dinutuximab beta recommends that, except for life threatening conditions, concomitant use of dinutuximab beta and corticosteroids should be avoided for 2 weeks prior to the first course of dinutuximab beta and for 1 week after the last course (UK). If concomitant use is required, close clinical and laboratory monitoring for the development of systemic infections and severe hematologic adverse effects is recommended both during and after discontinuation of therapy.

References
1	Cerner Multum, Inc. "UK Summary of Product Characteristics.".